|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
5R44CA124032-04
|
$1,917,582
|
$1,917,582
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
MOTILITY AND INVASION
|
5P01CA100324-10
|
$2,016,840
|
$201,684
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Translational Breast Cancer Research Training Program
|
5T32CA090221-10
|
$183,921
|
$45,980
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Lymphoma
|
2P50CA126752-06
|
$2,300,000
|
$552,000
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Enhancing T Cell Therapy of Cancer
|
5P01CA094237-10
|
$1,916,364
|
$958,182
|
Heslop, Helen
|
BAYLOR COLLEGE OF MEDICINE
|
|
Engineered tumor-specific T cells Resist Hypoxic-Tumor Immunosuppressive Attacks.
|
5R01CA142664-03
|
$308,958
|
$154,479
|
YOTNDA, PATRICIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-09
|
$2,300,000
|
$276,000
|
McDermott, David
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting Leukemic Stem Cells
|
5R01CA138211-05
|
$418,058
|
$418,058
|
TENEN, DANIEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant Cancers
|
5K99CA160350-02
|
$132,710
|
$66,355
|
Shi, Jinjun
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Sensitize Chemoresistant Breast Cancer by Nano-delivery of siRNA and Cisplatin
|
1F32CA168163-01
|
$52,190
|
$52,190
|
Xu, Xiaoyang
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Stem Cell-Engineered Tumor Immunity in Man
|
5P01CA132681-03
|
$2,898,964
|
$2,522,099
|
BALTIMORE, DAVID
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Nanosystems Biology Cancer Center 2
|
5U54CA151819-03
|
$2,463,138
|
$640,416
|
HEATH, JAMES
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Protein-DNA Drug Carriers for Tumor Targeting
|
5R01CA129822-04
|
$288,593
|
$144,297
|
MEDINA-KAUWE, LALI
|
CEDARS-SINAI MEDICAL CENTER
|
|
A NOVEL MICROFLUIDIC DEVICE FOR SELECTION AND OPTIMIZATION OF DRUG DELIVERY VEHIC
|
2R44CA139841-02A1
|
$633,309
|
$158,327
|
PRABHAKARPANDIAN, BALABHASKAR
|
CFD RESEARCH CORPORATION
|
|
MicroRNA in Acute Myeloid Leukemia
|
5R01CA159845-02
|
$317,475
|
$317,475
|
GRIMES, H
|
CHILDREN'S HOSPITAL MEDICAL CENTER CINCI
|
|
Targeted Improvement in Stem Cell Therapy for Leukemia and Bone Marrow Failure Sy
|
5R01CA157537-02
|
$317,475
|
$317,475
|
PANG, QISHEN
|
CHILDREN'S HOSPITAL MEDICAL CENTER CINCI
|
|
HAT Inhibition to Impair Foxp3+ Treg Function and Boost Anti-Tumor Immunity
|
5R01CA158941-02
|
$343,724
|
$103,117
|
Hancock, Wayne
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
CpG-siRNA Conjugates to Target Acute Myeloid Leukemia
|
5R01CA155367-02
|
$348,600
|
$348,600
|
KORTYLEWSKI, MARCIN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Development of Pro-SELEX Aptamer Selection Platform
|
2R44CA150490-02A1
|
$693,881
|
$346,941
|
DEMPSEY, PAUL
|
CYNVENIO BIOSYSTEMS, INC.
|
|
Mining B-catenin/BCL9 transcriptional complex for Multiple Myeloma therapeutics
|
5R01CA151391-03
|
$346,193
|
$173,097
|
CARRASCO, RUBEN
|
DANA-FARBER CANCER INSTITUTE
|
|
Aberrant activation of HGF/MET signaling as a therapeutic target in AML
|
5K08CA160660-02
|
$156,330
|
$78,165
|
Kentsis, Alex
|
DANA-FARBER CANCER INSTITUTE
|
|
Regulation of Targeted Gene Correction
|
5R01CA089325-12
|
$214,293
|
$214,293
|
Kmiec, Eric
|
DELAWARE STATE UNIVERSITY
|
|
Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
|
1P01CA154291-01A1
|
$1,651,535
|
$346,822
|
BIGNER, DARELL
|
DUKE UNIVERSITY
|
|
Targeting Translation Control in Malignant Glioma
|
2R01CA124756-06A1
|
$249,873
|
$249,873
|
GROMEIER, MATTHIAS
|
DUKE UNIVERSITY
|
|
RNA aptamers as cell surface receptor agonists and siRNA delivery agents
|
5R01CA129190-04
|
$251,191
|
$251,191
|
SULLENGER, BRUCE
|
DUKE UNIVERSITY
|
|
RNA Therapeutics for Pancreatic Cancer
|
5K08CA142903-02
|
$152,619
|
$152,619
|
White, Rebekah
|
DUKE UNIVERSITY
|
|
MDM2 regulates XIAP gene expression in cancer treatment
|
5R01CA123490-05
|
$249,581
|
$62,395
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Basis for Lymphomagenesis in Akt2 Transgenic Mice
|
5R01CA077429-13
|
$410,451
|
$102,613
|
TESTA, JOSEPH
|
FOX CHASE CANCER CENTER
|
|
Pediatric Oncology Research Training Program
|
2T32CA009351-34
|
$235,116
|
$47,023
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Career Development in Pediatric and Medical Oncology
|
5K12CA076930-14
|
$550,042
|
$110,008
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Antibody directed delivery of short interfering RNA for the treatment of ovarian
|
1K08CA163603-01A1
|
$170,631
|
$170,631
|
PALANCA-WESSELS, MARIA
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Seattle Cancer Consortium Breast SPORE
|
5P50CA138293-03
|
$2,300,000
|
$184,000
|
PORTER, PEGGY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeted therapy of ALL with gene-modified central memory T cells
|
5R01CA136551-04
|
$542,633
|
$271,317
|
Riddell, Stanley
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Pacific Ovarian Cancer Research Consortium
|
5P50CA083636-14
|
$2,296,158
|
$137,769
|
Urban, Nicole
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
DNA Replication Control and Its Application to Selective Killing of Cancer Cells
|
5R00CA136555-04
|
$241,529
|
$79,705
|
Zhu, Wenge
|
GEORGE WASHINGTON UNIVERSITY
|
|
Use of nanogels to target delivery of siRNA to cancer cells in mice
|
5R21CA155479-02
|
$247,687
|
$247,687
|
McDonald, John
|
GEORGIA INSTITUTE OF TECHNOLOGY
|
|
Melanoma-Targeted, Reversibly-Masked Nanoparticle for Systemic Delivery of Therap
|
N43CO110055-001
|
$150,021
|
$150,021
|
TEMPLETON, NANCY
|
GRADALIS, INC.
|
|
Designing Lymph Nodes for Cancer Immunotherapy
|
5R01CA148995-03
|
$336,129
|
$336,129
|
MULE, JAMES
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Gene Therapy and Radiation Therapy for Prostate Cancer
|
1R01CA160289-01A1
|
$303,988
|
$151,994
|
FREYTAG, SVEND
|
HENRY FORD HEALTH SYSTEM
|
|
ADAM 17 and glioma-tumor progression and treatment
|
5R01CA129446-04
|
$291,849
|
$96,310
|
JIANG, FENG
|
HENRY FORD HEALTH SYSTEM
|
|
Integrin-targeted siRNA delivery for therapeutic gene silencing in blood cancers
|
5R01CA139444-08
|
$439,110
|
$439,110
|
SPRINGER, TIMOTHY
|
IMMUNE DISEASE INSTITUTE, INC.
|
|
Genetic Therapy for Fanconi Anemia
|
5R01CA155294-02
|
$319,550
|
$319,550
|
CLAPP, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Durable CD4+ T-cell Tumor Immunity Following Gene-modified HPSC
|
5R01CA134014-04
|
$301,886
|
$301,886
|
Touloukian, Christopher
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Image-guided Prodrug and siRNA Targeting of Cancer
|
5R01CA138515-04
|
$330,091
|
$330,091
|
Bhujwalla, Zaver
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE In Prostate Cancer
|
5P50CA058236-18
|
$1,781,610
|
$356,322
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Targeting the let-7-HMGA2 Network in Metastatic Progression in Pancreatic Cancer
|
1R03CA164677-01A1
|
$81,000
|
$40,500
|
RESAR, LINDA
|
JOHNS HOPKINS UNIVERSITY
|
|
The Roles of HBXAP Gene in Ovarian Cancer
|
5R01CA129080-05
|
$330,091
|
$82,523
|
SHIH, IE-MING
|
JOHNS HOPKINS UNIVERSITY
|
|
Enhancing HPV-16 E6/E7 Specific Antitumor Immunity
|
2R01CA114425-06A1
|
$303,371
|
$151,686
|
WU, T.-C.
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE in Cervical Cancer
|
3P50CA098252-09S1
|
$90,231
|
$11,730
|
WU, T.-C.
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE in Cervical Cancer
|
5P50CA098252-09
|
$2,300,000
|
$299,000
|
WU, T.-C.
|
JOHNS HOPKINS UNIVERSITY
|
Total relevant funding to Gene Therapy for this search: $58,732,525
|